Brain Cancer Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Orbus Therapeutics, Kazia Therapeutics, Bayer, AstraZeneca, Immunomic Therapeutics, Kintara Therapeutics

January 20 15:48 2023
Brain Cancer Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Orbus Therapeutics, Kazia Therapeutics, Bayer, AstraZeneca, Immunomic Therapeutics, Kintara Therapeutics
The Brain Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Brain Cancer pipeline products will significantly revolutionize the Brain Cancer market dynamics.

DelveInsight’s “Brain Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Brain Cancer, historical and forecasted epidemiology as well as the Brain Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Brain Cancer market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

 

To Know in detail about the Brain Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Brain Cancer Market Insights

 

Brain Cancer Overview

A brain tumor, known as an intracranial tumor, central nervous system (CNS) tumors represent a group of diseases thathave in common the abnormal development of mass lesions in the brain, spinal cord or its coverings. A brain tumor can beclassified into two main groups, i.e., primary and metastatic.

 

Some of the key facts of the Brain Cancer Market Report: 

  • The Brain Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • The frequency of brain cancer increases with age, with more occurrences in individuals aged 65 and older
  • Exposure to certain industrial chemicals or solvents has been linked to an increased risk of developing brain cancer. Although it is not conclusive, evidence has found a higher incidence of certain types of brain tumors in individuals who work in oil refining, rubber manufacturing, and drug manufacturing
  • As per an article on Cancer.Net, brain tumors account for 85–90%of all primary CNS tumors. The article also quoted that an estimated 23,890 adults (13,590 men and 10,300 women) in the United States were likely to be diagnosed with primary cancerous tumors of the brain and spinal cord
  • According to the Brain Tumor UK, about 70–80% of primary brain tumors are High-Grade Gliomas. They occur most often between the ages of 46 and 50, affecting men more often than women
  • Key Brain Cancer Companies: Orbus Therapeutics, Kazia Therapeutics, Bayer, AstraZeneca, Immunomic Therapeutics, Kintara Therapeutics, Medicenna Therapeutics, Istari Oncology, and others
  • Key Brain Cancer Therapies: Eflornithine + Lomustine, Paxalisib, Regorafenib, Durvalumab, ITI-100, VAL-083, MDNA55, Lerapolturev, and others
  • The Brain Cancer epidemiology based on gender analyzed that Brain Cancer is slightly more common in men as compared to women

 

Get a Free sample for the Brain Cancer Market Report –

https://www.delveinsight.com/sample-request/brain-cancer-market

 

Key benefits of the Brain Cancer Market report:

  1. Brain Cancer market report covers a descriptive overview and comprehensive insight of the Brain Cancer Epidemiology and Brain Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Brain Cancer market report provides insights on the current and emerging therapies.
  3. Brain Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Brain Cancer market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Brain Cancer market.

 

Download the report to understand which factors are driving Brain Cancer epidemiology trends @ Brain Cancer Epidemiological Insights 

 

Brain Cancer Market  

The dynamics of the Brain Cancer market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

“According to the estimates, the highest market size of Brain Cancer was found in theUnitedStates and the least was in the United Kingdom across the 7MM. Besides, the upcoming therapiesof Brain Cancer are expected to combat the current unmet needs faced by the patients with BrainCancer and add to the overall growth of the Brain Cancer market size.”

 

Brain Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Brain Cancer Epidemiology Segmentation:

The Brain Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Brain Cancer
  • Prevalent Cases of Brain Cancer by severity
  • Gender-specific Prevalence of Brain Cancer
  • Diagnosed Cases of Episodic and Chronic Brain Cancer

 

Brain Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Brain Cancer market or expected to get launched during the study period. The analysis covers Brain Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.  

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Brain Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Discover more about therapies set to grab major Brain Cancer market share @ Brain Cancer market forecast 

 

Brain Cancer Therapies and Key Companies

  • Eflornithine + Lomustine: Orbus Therapeutics
  • Paxalisib: Kazia Therapeutics
  • Regorafenib: Bayer
  • Durvalumab: AstraZeneca
  • ITI-100: Immunomic Therapeutics
  • VAL-083: Kintara Therapeutics
  • MDNA55: Medicenna Therapeutics
  • Lerapolturev: Istari Oncology

 

Brain Cancer Market Drivers

  • Robust Pipeline Activity
  • Upcoming Launches and Approval
  • Increasing Awareness Programs
  • Increase in Reimbursement and Insurance Policies
  • Interventions that can Cross the Blood–Brain Barrier
  • Development of Intratumoral therapies

 

Scope of the Brain Cancer Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Brain Cancer Companies: Orbus Therapeutics, Kazia Therapeutics, Bayer, AstraZeneca, Immunomic Therapeutics, Kintara Therapeutics, Medicenna Therapeutics, Istari Oncology, and others
  • Key Brain Cancer Therapies: Eflornithine + Lomustine, Paxalisib, Regorafenib, Durvalumab, ITI-100, VAL-083, MDNA55, Lerapolturev, and others
  • Brain Cancer Therapeutic Assessment: Brain Cancer current marketed and Brain Cancer emerging therapies
  • Brain Cancer Market Dynamics: Brain Cancer market drivers and Brain Cancer market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Brain Cancer Unmet Needs, KOL’s views, Analyst’s views, Brain Cancer Market Access and Reimbursement 

 

Brain Cancer Market Barriers

  • Use of Off-label Therapies and Generics
  • High-treatment Costs
  • Fewer Patients Available for Clinical Trials for current therapies
  • High Recurrence Rate
  • Multiple Treatment Challenges

 

Table of Contents 

1. Brain Cancer Market Report Introduction

2. Executive Summary for Brain Cancer

3. SWOT analysis of Brain Cancer

4. Brain Cancer Patient Share (%) Overview at a Glance

5. Brain Cancer Market Overview at a Glance

6. Brain Cancer Disease Background and Overview

7. Brain Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Brain Cancer 

9. Brain Cancer Current Treatment and Medical Practices

10. Brain Cancer Unmet Needs

11. Brain Cancer Emerging Therapies

12. Brain Cancer Market Outlook

13. Country-Wise Brain Cancer Market Analysis (2019–2032)

14. Brain Cancer Market Access and Reimbursement of Therapies

15. Brain Cancer Market Drivers

16. Brain Cancer Market Barriers

17.  Brain Cancer Appendix

18. Brain Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

To know more about Brain Cancer treatment, visit @ Brain Cancer Medications 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

  Categories:
view more articles

About Article Author